Li Mao
Fortune : 350 255 $ au 31/05/2026
Fortune : 350 255 $ au 31/05/2026
Li Mao currently works at Legend Biotech Corp., as Independent Director from 2022.
Dr. Mao also formerly worked at Xcovery Holding, Inc., as Chief Executive Officer from 2018 to 2021, Livzon Pharmaceutical Group, Inc., as Chief Executive Officer in 2021, Betta Pharmaceuticals Co., Ltd., as Director, Chief Medical Officer & Senior VP from 2018 to 2021, Sino Biopharmaceutical Ltd., as Chief Medical Officer from 2021 to 2022, SciClone Pharmaceuticals (China) Co. Ltd., as Chief Medical Officer from 2022 to 2025, Johnson & Johnson, as Vice President from 2016 to 2018, The University of Texas M.D.
Anderson Cancer Center, as Professor from 2004 to 2009, and the University of Maryland Baltimore County, as Professor from 2009 to 2016.
Dr. Mao received his doctorate degree from Nanjing Medical University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LEGEND BIOTECH CORP. 0,01 % | 18/03/2026 | 25 792 ( 0,01 % ) | 350 255 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Directeur/Membre du Conseil | 02/08/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
SciClone Pharmaceuticals (China) Co. Ltd.
SciClone Pharmaceuticals (China) Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Directeur Technique/Scientifique/R&D | 01/02/2025 |
| SINO BIOPHARMACEUTICAL LIMITED | Directeur Technique/Scientifique/R&D | 01/06/2022 |
| LIVZON PHARMACEUTICAL GROUP INC. | Directeur Général | 01/04/2021 |
Xcovery Holding, Inc.
Xcovery Holding, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology focused bio-pharmaceutical company | Directeur Général | 01/03/2021 |
| BETTA PHARMACEUTICALS CO., LTD. | Directeur Technique/Scientifique/R&D | 01/03/2021 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Johnson & Johnson
Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Livzon Pharmaceutical Group, Inc.
Livzon Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical, chemical preparation medicines and vaccines products | Health Technology |
Xcovery Holding, Inc.
Xcovery Holding, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology focused bio-pharmaceutical company | Health Technology |
Sino Biopharmaceutical Ltd.
Sino Biopharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Operates as an investment holding company, which engages in the manufacturing and selling of pharmaceutical products | Health Technology |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
Nanjing Medical University
Nanjing Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which focuses on the discovery, development and commercialization of drugs | Health Technology |
University of Maryland Baltimore County
University of Maryland Baltimore County Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Legend Biotech Corp.
Legend Biotech Corp. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | Health Technology |
SciClone Pharmaceuticals (China) Co. Ltd.
SciClone Pharmaceuticals (China) Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national